This trial included 104 patients diagnosed with depression, making it the largest randomized, controlled, blinded, multicenter trial of accelerated deep TMS protocol.2 The study also did not rely on neuronavigation equipment like fMRI.2The accelerated Deep TMS group compared with the standard Deep TMS group had comparable measures of depression scores and response and remission rates. Deep TMS, BrainsWay’s TMS system, is currently indicated to treat depressive episodes and decrease comorbid anxiety symptoms. In addition, we are actively seeking updates to reimbursement to match the new accelerated protocol, which will help with patient adoption,” added Levy. BrainsWay receives FDA clearance for accelerated Deep TMS protocol for non-invasice treatment of major depressive disorder. BrainsWay reports positive results from multicenter randomized study of accelerated Deep TMS for major depressive disorder (MDD).